Navigation Links
PEAK Surgical Introduces PlasmaBlade(TM) Product Line Extensions for Use in General Surgery
Date:10/28/2008

- PlasmaBlade Needle and PlasmaBlade EXT Extend PlasmaBlade Family of Tissue Dissection Tools, Which Have Been Used in More Than 150 Surgical

Procedures Since FDA Clearance in July -

PALO ALTO, Calif., Oct. 28 /PRNewswire/ -- PEAK Surgical, Inc., a medical device company that has developed a new tissue dissection system based on a proprietary technology, has introduced two extensions to its PEAK PlasmaBlade(TM) family of disposable surgical cutting and coagulation tools. The PlasmaBlade Needle, which has a fine needlepoint tip, is specifically designed for ultra-precise surgical procedures. The PlasmaBlade EXT is designed for use in surgical procedures requiring an extended-reach tip.

In July, the U.S. Food and Drug Administration granted PEAK Surgical 510(k) clearance to market the PEAK(R) Surgery System, including the PlasmaBlade 4.0, for use in general surgery. The PlasmaBlade 4.0 is designed to be used to cut through all types of soft tissue, including skin, fat and muscle. All of the PlasmaBlade tissue dissection tools are used in conjunction with PEAK's PULSAR(TM) Generator, which provides pulsed plasma radiofrequency energy to the PlasmaBlade to create surgical incisions and control bleeding. They offer the exacting control of a scalpel and the coagulation of traditional electrosurgery without extensive collateral damage.

Since FDA clearance, surgeons have used the PlasmaBlade 4.0 in more than 150 surgical procedures, including in general, gynecologic, orthopedic, cardiothoracic, plastic and reconstructive surgeries.

"The PlasmaBlade will change the way our practice performs surgery because we will no longer need to switch between a scalpel and a traditional electrosurgery device depending on the surgical field and type of tissue we are cutting," said Dr. Jonathan S. Berek, professor and chair of the Department of Obstetrics and Gynecology at Stanford University School of Medicine and co-director of the
'/>"/>

SOURCE PEAK Surgical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. Pioneer(R) Surgical Technology Announces First Human Implants of New nanOss(TM)-Cervical Fusion Device
2. Pioneer(R) Surgical Technology Announces Market Release of FortrOss(TM), a Next Generation Bone Void Filler
3. CryoLife Hosts Worldwide Surgical Congress for the Ross Procedure
4. Reliant Technologies Announces FDA 510(K) Clearance of New Handpieces for Skin Resurfacing and Surgical Applications
5. New Opportunities in X-Ray Based Surgical Navigation With Ziehm NaviPort 3D
6. Sound Surgical Technologies Welcomes Dr. Mark Schafer as New Chief Technology Officer and Vice President of Research & Development
7. Solos Endoscopy, Inc. Implements Strategy to Capitalize on $30 Billion Minimally Invasive Surgical Product Market
8. Baxter Announces Licensing Agreement for Innocolls Gentamicin Surgical Implant in the United States
9. PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in General Surgery
10. Pioneer(R) Surgical Technology, Inc. Announces the Market Launch of the SlimFuse(TM) Anterior Cervical Plate System
11. Healthcare Facility Managers Learn to Optimize Surgical Suites at 2008 ASHE Annual Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...FirstCall/ -- Omeros Corporation (Nasdaq: OMER ) ...e third quarter ended September 30, 2009. For the ...rted a net loss of $3.9 million, or $1.34 per shar...2.54 per share, for the same period in 2008. For t...ny reported a net loss of $15.5 million, or $5.29 ...
(Date:11/19/2009)...-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS ), a...er to its shareholders, discussing the Company,s a...aceuticals Holdings, Inc. (CHBP), an integrated bi...ublic of China. The merger gives NeoStem a control.... Ltd., CHBP,s primary operating subsidiary and a ...
(Date:11/19/2009)...mber 19 MONITORING FORCE GmbH,anno...Flibanserin in the,indication treatment-relevant l...for orphan drug status designation with the Europe...nesia is a complication of the mainstay,treatment ...me of those,affected, since it may be disabling fo...
(Date:11/19/2009)...ne Synthesis Companies Form International Gene Syn...ces in Risk Reduction ,Five Member Companies Rep...city , (PRWEB) November 1...synthesis companies today announced agreement that...omote biosecurity in the gene synthesis industry. ...
Breaking Biology Technology:Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 4
...lant to Provide an Attractive Domestic Alternative...y 18 Fulcrum BioEnergy, Inc.,today announced that...n,with its plans to build one of the first commerc...icipal solid waste to ethanol. The plant will,proc...olutionizing waste,disposal while creating a much ...
...ignificantly Strengthens Teva,s Market Leadership ...n Key Global Markets, Acquisition Expected to Be ...RUSALEM and MONTVALE, N.J., July 18 Teva,Pharmace...harmaceuticals,Inc. (NYSE: BRL ) announced today ... which Teva will acquire Barr, the fourth largest ...
... CAMBRIDGE, Mass., July 17, 2008 -- The Defense A...ed a $1.2 million grant to an interdisciplinary te...ace enhanced Raman scattering (SERS) for the first... phases of the development program are completed, ... million in funding. , Ken Crozier, Assistant Pro...
Other Biology Technology:Fulcrum BioEnergy Announces Plans to Build One of the First Commercial-Scale Ethanol Plants Using Municipal Solid Waste as Feedstock 2Fulcrum BioEnergy Announces Plans to Build One of the First Commercial-Scale Ethanol Plants Using Municipal Solid Waste as Feedstock 3Teva to Acquire Barr 2Teva to Acquire Barr 3Teva to Acquire Barr 4Teva to Acquire Barr 5Teva to Acquire Barr 6Teva to Acquire Barr 7Teva to Acquire Barr 8DARPA awards research team $1.2M grant to study surface enhanced Raman scattering 2
(Date:11/20/2009)...igin of biological molecules like RNA and DNA is h...from simple precursors. Now, in a study appearing ...nstructed one of the earliest evolutionary steps y...subunits using nothing but warm water. , Many r...iological molecules present, before DNA and protei...
(Date:11/20/2009)... - Bacteria possess an ingenious mechanism for pre... the cell. This is the new finding of a team of bi...e sciences research institute in Flanders, Belgium... scientists made this discovery by modifying the D... By means of this model organism, they have uncove...
(Date:11/20/2009)...Research Center (ERC) has been awarded a grant fro...ethods of recovering and reusing the heat that wou...ression process in a carbon capture system. The go... capture and sequestration, or storage (CCS), and ...emitted into the atmosphere by coal-fired power pl...
Breaking Biology News(10 mins):Biologists discover bacterial defense mechanism against aggressive oxygen 2Lehigh receives grant to reduce cost of carbon capture at coal-fired power plants 2Lehigh receives grant to reduce cost of carbon capture at coal-fired power plants 3Ferns took to the trees and thrived 9095 1Ferns took to the trees and thrived 9095 2iMedExchange Launches Health Policy Resource Center 50653 1iMedExchange Launches Health Policy Resource Center 50653 2WellPoints Contribution To Drug Formulary Evaluation Standards Highlighted in ISPOR Publication 50651 1WellPoints Contribution To Drug Formulary Evaluation Standards Highlighted in ISPOR Publication 50651 2WellPoints Contribution To Drug Formulary Evaluation Standards Highlighted in ISPOR Publication 50651 3
... scientists offer a compendium of air pollution re...n humans and the environment, while addressing the... fire as a land management tool. , The 686-page b...rts from various science disciplines who studied s...sia, and Australia from prehistoric times to the p...
... toward winter, many people will begin to experien...evastating. , About 6 percent of the U.S. popula...SAD, a sometimes-debilitating depression that begi...rers may even find it difficult to get out of bed ... understood, is often treated with "light therapy,...
...t cheap piece of scrap iron before you toss it in .... Someday soon, much of the world might also. , Z...eering, recently concluded a five-year research pr...versity in Shanghai used two million pounds of iro... , The project, carried out in Shanghai, was the ...
Other Biology News:Book explores global implications of wildland fire smoke 2Seasonal affective disorder may be linked to genetic mutation, study suggests 2A green future for scrap iron 2A green future for scrap iron 3
Rabbit Anti-Human Naked1 Polyclonal Antibody, Unconjugated from Cell Signaling Technology
Rabbit Anti-NF-kB p65, phospho (Ser345) Antibody, Unconjugated from Spring Bioscience
Anti-NSP-C (Neuroendocrine-Specific-Protein) Monoclonal Antibody, Unconjugated, Clone RNL-4 from CHEMICON
Rabbit Anti-Human ADAMTS-4, disintegrin-like domain Antibody, Unconjugated from CHEMICON
Biology Products: